NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title Type and code Publication date Action 1. Nutrition support in adults: oral nutrition support, enteral tube feeding and parenteral nutrition (CG32) February 3. Colon Can. Adjuvant - Capecitabine and oxaliplatin (TA100) March 4. Docetaxel in HRPC (TA101) June 5. Management of Atrial Fibrillation (CG36) June 6. Colorectal Laparoscopic surgery review (TA105) August 7. Hepatitis C Peg interferon and ribavirin (TA106) August 8. Breast (early) Trastuzumab (TA107) August
9. Breast cancer (early) Docetaxel (TA109) September 10. Breast cancer (early) Paclitaxel (TA108) September 11. Follicular lymphoma Rituximab (TA110) September 12. Breast (early) hormonal treatments (TA112) November 13. Gemcitabine for the treatment of early Breast ca. (TA116) January 14. Bevacizumab and cetuximab in metastatic CRC (TA118) January 15. Laparoscopic Radical Prostatectomy (IPG193) November 16. PDT for advanced/early oesophageal ca. (IPG200) December 18. Leukemia (Lymphocytic) Fludarabine (TA119) February 20. MI secondary prevention (CG48) May
21. Venous thromboembolism (CG46) April 22. Glioma carmustine implants (TA121) July 23. Glioma temozolomide (TA121) July 24. Alteplase for the treatment of acute ischaemic heart disease (TA122) July 25. Management of faecal incontinence (CG49) June 26. Pemetrexed for the treatment of NSCLC (TA124) August 27. Bortezomib for the treatment of multiple myeloma (TA129) October 28. Pemetrexed for the treatment of malignant pleural mesothelioma (TA135) January 29. Lymphoma (follicular NHL) rituximab (TA137) February 30. Prostate cancer diagnosis and treatment (CG58) February
31. Inadvertent peri-operative hyperthermia (CG65) April 32. Epoetin alfa, epoetin beta and darbepoetin alfa for cancer induced anaemia (TAG142) May 33. Cetuximab for the treatment of locally advanced SCC of H&N (TAG 145) June 34. Erlotinib in NSCLC (TAG162) November 35. Metastatic spinal chord compression (CG75) November 36. Surgical site infection (CG74) October 37. Spinal cord stimulation for chronic pain of neuropathic origin (TAG159) October 38. Influenza (prophylaxis) amantadine, oseltamir and zanamivir (TAG158) September 39. Medicines Adherence (CG76) January 2009 40. Early and locally advanced Breast ca. (CG80) February 2009
51. Renal Cell Ca. (TAG178) August 2009 52. Topotecan in recurrent stage IVb cervical ca. (TAG183) October 53. Topotecan (oral) in relapsed SCLC (TAG184) November 54. Trabectadin for treatment of advanced STS (TAG185) February 55. Venous thrombo embolism reducing the risk (CG92) February 56. Chest pain of recent onset (CG95) March 57. Unstable angina in NSTEMI (CG96) March 58. Pemetrexed maintenance (TA190) June 59. Skin Tumours including melanoma (CSGSTIM) May 60. Hepatocellular Carcinoma (advanced & metastatic) Sorafenib 1 st line (TA189) May
61. Imatanib for adjuvant GIST (TA196) August 62. Denosumab therapy induced bone loss in prostrate ca. July 63. Trastuzumab in GI ca. (HER2+ in combination with Cis/X or Cis/5FU) (TA208) November 64. Imatinib in GIST dose escalation 600mg or 800mg (TA209) November 65. Bevacizumab in mcrc (in combination with FOLFOX/XELOX (TA212) December 66. Sedation in children + young people for diagnostic and therapeutic procedures (CG112) December 67. Bendamustine 1 st line CLL for patients not suitable for Fludarabine (TA216) February 68. Bevacizumab in combination with a taxane for breast Ca (TA214) February 69. Azacitidine in line with licensed indication for MDS, AML, CML (TA218) March 70. Pazopanib for 1 st line Renal cell carcinoma (TA215) February
71. Everolimus in 2 nd line RCC (TA219) April 72. Ovarian ca. guidelines (CG122) April 73. Lung ca. guidelines (CG121) April 74. Romiplostim in chronic ITP (TA221) April 75. Erlotinib in maintenance NSCLC (TA227) June 76. Rituximab in maintenance follicular lymphoma following response to 1 st line therapy. (TA226) June 77. Rituximab as 1 st line maintenance in NHL (TA226) June 78. Bortezomib and Thalidomide as 1 st line in MM (TA228) July 79. Bivalirudin for treatment of ST segment MI (TA230) July 80. Hyperglycaemia in ACS (CG130) October
81. Fulvestrant in metastatic Breast ca. (TA239) December 82. Anaphylaxis (CG134) December 83. Dasatanib, high dose imatanib & nilotinib in CML (TA241) January 84. Cetuximab (in combination), Bevacizumab (in combination) and Panatumumab (monotherapy) for treatment of CRC after 1 st line chemotherapy 85. Follicular Lymphoma (stage III/IV), rituximab in combination with specific chemotherapy regimens. 86. Patient Experiences in Adult NHS Services. (TA242) (TA243) (CG138) January January February 87. Dabigatran for prevention or treatment of stroke and embolism in patients with AF (TA249) February 88. Eribulin in metastatic breast (TA250) March 89. Dasastanib, nilotinib & imatanib (standard dose) in 1 st line CML (review of (TAG70) March 90. Rivaroxaban (TA256) May
91. Lapataninb ad Trastuzumab in combination with an AI (TA257) June 92. Erlotinib (TA258) June 93. Rivaroxaban (TA261) July 94. Acute upper GI bleeding (CG141) June 95. VTE diseases (CG144) June 96. Bevacizumab in mbreast ca. (TA263) August 97. Neutropenic Sepsis (CG151) September 98. Denosumab (TA265) October 99. Ipilimumab in melanoma (TA268) December 100. Vemurafenib in melanoma (TA269) December
101. Vinflunine for urothelial tract carcinoma (TA272 ) January 2013 102. Bevacizumab in combination in ovarian ca. 103. Bevacizumab in ovarian, fallopian tube & primary peritoneal ca. (TA284) May 2013 (TA285) May 2013 104. Familial Breast Cancer (CG164) July 2013 105. Dapagliflozin in type II diabetes (TA288) July 2013 106. Ruxilitionib in Myelofibrosis (TA289) July 2013 107. Rivaroxaban in PE and recurrent VTE (TA287) July 2013 108. Myocardial infarction with ST elevation (CG167) July 2013 109. Eltombopag in chronic ITP (TA293) July 2013 110. Everolimus in combination with exemestane in advanced HER2+ve breast ca (TA295) August 2013
111. Crizotanib for previously treated non small cell lung cancer in associated with anaplastic lymphoma kinase infusion gene. 112. Bosutinib for previously treated chronic myeloid leukemia 113. Intravenous fluid therapy in adults in hospital (TA296) September 2013 (TA199) November 2013 (CG174) December 2013 114. Pixantrone in multiple relapsed (TA306) February 2014 refractory aggressive NH B cell lymphoma. Ian Chau to be made aware. 115. Clinical guideline for prostate cancer (CG 175) January 2014 116. Aflibercept in combination with irinotecan & 5FU (Folfiri) in mcrc following progression with oxaliplatin 117. Pemetrexed in maintenance treatment in NSCLC (TA307) March 2014 (TA309) April 2014 118. Afatanib in EGFR+ve locally advanced or metastatic NSCLC in TKI naïve patients 119. Bortezomib +ve. Pre high dose chemotherapy and autologous stem cell transplant. (TA310) April 2014 (TA311) April 2014 120. Management of atrial fibrillation (CG180) June 2014
121. Enzalutamide in relapsed prostrate ca. previously treated with docetaxel (TA316) July 2014 122. Ipilimumab in previously untreated (TA319) July 2014 advanced unresectable melanoma +ve, Melanoma unit aware of guidance and implementation date 123. Advanced breast cancer (update CG81) July 2014 124. Drug Allergy: Diagnosis & management of drug allergy in adults Children and Young persons. 125. Dabrafenib for the treatment of BRAF V600 mutation positive, unresectable, advanced or metastatic melanoma. 126. Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142). 127. Sipuleucel-T. Treatment of asymptomatic/minimally symptomatic hormone relapsed prostate cancer. 128. Axitinib. Treatment of advanced RCC after failure of prior TKI s. 129. Rifaxamin. Treatment of hepatic encephalopathy. (CG183) September 2014 (TA321) October 2014 (TA323) November 2014 (TA332) February 2015 (TA333) February 2015 (TA337) March 2015
130. Pomalidomide Relapsed refractory myeloma previously treated with thalidomide & bortezomib. 131. Medicines Optimisation: the safe and effective use of medicines to enable best possible outcomes. 132. Apixaban for the treatment and secondary prevention of DVT and/or PE. 133. Obinutuzumab in combination with chlorambucil for untreated CLL. 134. Ofatumumab in combination with chlorambucil or bendamustine for untreated CLL. 135. Nintedanib with docetaxel, for adenocarcinoma of locally advanced, metastatic or locally recurrent NSCLC 136. Bevacizumab Relapsed platinum resistant ovarian, fallopian tube or primary peritoneal ca. 137. Edoxaban Treatment and prevention of DVT & PE. 138. Pembrolizumab in advanced melanoma after disease progression with ipilimumab (& dabrafenib, vemurafenib & trametanib in BRAF VB600+ve patients) 139. Idelalisib in combination with rituximab as a possible treatment option for : a. untreated CLL (17p deletion of (TA338) March 2015 (NG5) March 2015 (TA341) June 2015 (TA343) June 2015 (TA344) June 2015 (TA347) July 2015 (TA353) August 2015 Appraisal terminated. (TA354) August 2015 (TA357) October 2015 (TA359) October 2015
TP53 mutation) b. CLL previously treated but has come back within 2 years. Clinical unit leads aware. 140. nabpaclitaxel in combination with gemcitabine in previously untreated metastatic pancreatic ca. 141. Pembrolizumab for advanced melanoma not previously treated with ipilumumab 142. Trastuzumab emantansine for treating HER2 (+ve) unresectable locally advanced or metastatic Breast ca. after treatment with trastuzumab and a taxane. 143. Erlotinib and gefitinib for treating NSCLC that has progressed on prior therapy. 144. Bortezomib for previously treated mantle cell lymphoma. 145. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. In patients with no or mild symptoms after androgen deprivation therapy has failed 146. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy, (TA360) October 2015 (TA366) November 2015 (TA371) December 2015 (TA374) December 2015 (TA370) December 2015 (TA377) January 2016 (TA381) January 2016
following 3 or more courses of platinum based chemotherapy 147. Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380) January 2016 148. Radium-223 dichloride for treating (TA376) January 2016 hormone-relapsed prostate cancer with bone metastases, following treatment with docetaxel 149. Ramucirumab for treating advanced gastric cancer or gastro oesophageal (TA378) January 2016 junction adenocarcinoma previously treated with chemotherapy 150. Myeloma: diagnosis and management (NG35) February 2016 151. Nivolumab as a treatment option for advanced resectable melanoma 152. Topotecan, pegylated liposomal doxorubicin, paclitaxel, trabectadin & gemcitabine in recurrent ovarian ca. (replacing TA91 & TA222) 153. Abiraterone in metastatic hormone relapsed prostate ca. before chemo. (TA384) February 2016 (TA389) April 2016 (TA387) April 2016 154. Canagliflozin, dapagliflozin & empagliflozin as monotherapies for treating type II diabetes (TA390) May 2016 155. Cabazitaxel in HRPC post docetaxel (TA391) May 2016
156. Ceritinib in previously treated anaplastic lymphoma kinase +ve NSCLC (who have previously had crizotinib) 157. Trametanib & dabrafenib unresectable or metastatic melanoma that has BRAF V600 mutation 158. Bosutinib in CML. Chronic, accelerated and blast phase (ph+ve) 159. Pemetrexed maintenance in NSNSCLC (after pemetrexed/cisplatin) 160. Ramucirumab in locally advanced NSCLC 161. Degarelix in advanced hormone dependent prostate ca (with spinal metastases) 162. Trifluidine-tipiracil in previously treated metastatic 163. Crizotinib for untreated anaplastic lymphoma kinase +ve advanced non small cell lung cancer 164. Pegasparagase for treating acute lymphoblastic leukaemia (untreated and newly diagnosed) 165. Talimogene laherparepvec in unresectable metastatic melanoma when immunotherapies are not suitable (TA395) June 2016 (TA396) June 2016 (TA401) August 2016 (TA402) August 2016 (TA403) August 2016 (TA404) August 2016 (TA405) August 2016 (TA406) September 2016 (TA408) September 2016 (TA410) September 2016
166. Radium 223 in hormone relapsed prostate cancer (with no known visceral metastases) 167. Necitimumab for untreated advanced or metastatic squamous NSCLC (in combination with gemcitabine & cisplatin). 168. Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutationpositive melanoma 169. Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (via CDF) 170. Nivolumab in advanced renal cell carcinoma (+ve). 171. Everolimus with examestane fro advanced breast ca. 172. Crizotinib for previously treated anaphylactic lymphokinase 173. Eribulin fro locally advanced or metastatic breast ca. 174. Pertuzumab in neoadjuvant HER2+ve Breast ca. 175. Dasatinib, nilotinib & HD imatinib in resistant/intolerant CML (TA412) September 2016 (TA411) September 2016 (TA414) October 2016 (TA416) October 2016 (TA417) November 2106 (TA421) December 2016 (TA422) December 2016 (TA423) December 2016 (TA424) December 2016 (TA425) December 2016
176. Dasatinib, nilotinib & imatinib in untreated CML 177. Pomalidommide in MM previously trrated with lenalidomide & bortezomib 178. Pembrolizumab fro PDL1 +ve NSCLC (after chemotherapy) (TA426) December 2016 (TA427) January 2017 (TA428) January 2017 179. Ibrutinib in previously treated CLL. (TA429) January 2017 180. Everolimus for advanced RCC (after previous treatment). James Larkin aware of guidance. 181. Cetuximab & panitumumab for previously untreated mcrc (RAS wild type) in combination with FOLFOX/FOLFIRI 182. Nanoliposomal irinotecan for pancreatic ca. after gemcitabine (metastatic adeno ca.) (TA432) February 2017 (TA439) March 2017 (TA440) April 2017 185. Brentuximab for treating CD30+ve (TA446) June 2017 186. Pembrolizumab for untreated PDL1 +ve metastatic NSCLC (TA447) June 2017 188. Blinatumumab in Ph+ve ALL (TA450) June 2017
187. Ponatinib in CML & ALL (TA451) June 2017 183. Carfilzomib for previously treated MM (TA457) July 2017 184. Trastuzumab emtansine for HER2+ advanced Breast ca. (TA458) July 2017 189. Nivolumab in relapsed/refractory HL TA462 July 2017 191. Cabozantanib in advanced RCC (post VEGF therapy) 190. Olaratumumab in combination with doxorubicin in STS 193. Obinutuzumab plus bendamustine in follicular lymphoma 194. Cetuximab in recurrent metastatic squamous cell ca. 192. Pemetrexed maintenance in advanced NSCLC 196. Sorafenib in advanced hepatocellular ca. TA463 August 2017 TA465 August 2017 TA472 August 2017 TA473 August 2017 TA190 August 2017 TA474 September 2017
195. Abraxane plus gemcitabine in untreated metastatic pancreatic ca. TA476 September 2017 197. Relapsed refractory systematic anaplastic large cell lymphoma (ECOG 0-1) TA 478 October 2017 198. Nivolumab in previously treated NSCLC TA483 November 2017 199. Venetoclax in CLL TA487 November 2017 200. Regorafenib in previously treated or unresectable GIST TA488 November 2017 201. Vismodogib in basal cell carcinoma TA489 November 2017 202. Ibrutinib in Waldenstroms Macroglobulinaemia 203. Atezolizumab in untreated locally advanced or metastatic urothelial cancer TA491 November 2017 TA492 December 2017